A new discovery published online in The FASEB Journal (http://www.fasebj.org) promises to help physicians identify patients most likely to benefit from breast cancer drug therapies.
If the compound, called "Nanobody," proves effective in clinical trials, it would represent a significant advance for breast cancer drug therapy because some drugs are effective only in some people. In addition, some drugs have side effects that may cause damage to vital organs, making it more crucial for physicians to get the right treatment to the right patient the first time around.
"What makes Nanobodies so promising is that they are robust, small enough for rapid elimination from the body, and easy to produce at a relatively low cost," said Ilse Vaneycken, M.Sc., a researcher involved in the work.
To make this discovery, Vaneycken and her colleagues started with the target of the therapeutic drugs (HER2) and immunized a dromedary camel to raise special antibodies unique to this species. Next, all unnecessary parts of the camel's antibodies were removed and cloned in bacteria. Of 100 million bacterial clones, the team selected those that produced the 40 Nanobodies that recognized¨D or bound to¨Dthe same site targeted by therapeutic drugs. Of this group, the team screened for compounds that picked out breast cancer cells bearing the genetic tag HER2. Their lead compound did just that, and without blocking access to cancer-killing drugs now in use. Other properties of Nanobodies, such as good expression, stability, and visibility¨Denabled breast cancer tumors to be stained and seen rapidly¨Dwere also exploited.
"The scientists went over the hump to get to the lump so to speak," said Gerald Weissmann, M.D., Editor-in-Chief of The FASEB Journal. "This technique not only promises to help doctors target cancer cells with effective drugs today, but to pick out other discrete cancer targets in the future."
Receive monthly highlights from The FASEB Journal by e-mail or updates as they happen on Facebook. Sign up at http://www.faseb.org/fjupdate.aspx or "like" the Federation of American Societies for Experimental Biology on Facebook. The FASEB Journal (http://www.fasebj.org) is published by the Federation of the American Societies for Experimental Biology (FASEB) and celebrates its 25th anniversary in 2011. Over the past quarter century, the journal has been recognized by the Special Libraries Association as one of the top 100 most influential biomedical journals of the past century and is the most cited biology journal worldwide according to the Institute for Scientific Information.
FASEB comprises 23 societies with more than 100,000 members, making it the largest coalition of biomedical research associations in the United States. FASEB enhances the ability of scientists and engineers to improve¡ªthrough their research¡ªthe health, well-being and productivity of all people. FASEB's mission is to advance health and welfare by promoting progress and education in biological and biomedical sciences through service to our member societies and collaborative advocacy.
Details: Ilse Vaneycken, Nick Devoogdt, Naomi Van Gassen, C¨¦cile Vincke, Catarina Xavier, Ulrich Wernery, Serge Muyldermans, Tony Lahoutte, and Vicky Caveliers. Preclinical screening of anti-HER2 nanobodies for molecular imaging of breast cancer. FASEB J. doi:10.1096/fj.10-180331 ; http://www.fasebj.org/content/early/2011/04/08/fj.10-180331.abstract
Cody Mooneyhan | EurekAlert!
Novel mechanisms of action discovered for the skin cancer medication Imiquimod
21.10.2016 | Technische Universität München
Second research flight into zero gravity
21.10.2016 | Universität Zürich
14.10.2016 | Event News
14.10.2016 | Event News
12.10.2016 | Event News
21.10.2016 | Health and Medicine
21.10.2016 | Information Technology
21.10.2016 | Materials Sciences